Amgen opts to DARP-out after seeing early data from $50M Molecular Partners collab
Amgen opts to DARP-out after seeing early data from $50M [...]
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Editas sees clinical promise with new FDA pediatric disease tag [...]
Pfizer-Valneva’s Lyme disease vaccine performs even better in children
Pfizer-Valneva’s Lyme disease vaccine performs even better in children aarmstrong [...]
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration [...]
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaning
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues [...]
Another setback for Axsome as migraine med expected to get a no from FDA
Another setback for Axsome as migraine med expected to get [...]
Vallon looks for escape route a month after sole clinical asset fails in clinic
Vallon looks for escape route a month after sole clinical [...]
Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data
Astellas takes $170M hit as DMD gene therapy plan unravels [...]
The Clever-1? Faron hails melanoma data despite lack of responses
The Clever-1? Faron hails melanoma data despite lack of responses [...]
Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stint
Chutes & Ladders—Romanelli returns to Merck to lead international human [...]